Our data along with 3K3A-APC’s clinical safety profile [12] and well-established, anti-inflammatory blood barrier protection and neuroprotective activities [1,2] suggests that 3K3A-APC should be considered as a new therapeutic option for retinal disease. Here, APC is linked to Abnormal retinal morphology.